Capricor Therapeutics Faces September 28, 2026 Deadline for Class Action Lawsuit Claims

Investors in Capricor Therapeutics, Inc. (NasdaqGS: CAPR) are urged to take action before the September 28, 2026, deadline to file claims for a class action lawsuit. The law firm Kahn Swick & Foti, LLC (KSF), along with partner Charles C. Foti, Jr., former Attorney General of Louisiana, has notified shareholders of the opportunity to participate.

The lawsuit alleges that Capricor Therapeutics may have issued misleading or incomplete information to investors regarding the company's business operations. This alleged misinformation could have negatively impacted the stock's value, leading to financial losses for certain shareholders.

KSF is representing investors who purchased Capricor stock during a specified period and allegedly suffered damages. The firm is seeking individuals who meet the criteria to join the class action. Interested parties must contact KSF before the September 28, 2026 deadline to submit their claims and receive further instructions.

Capricor Therapeutics is a biotechnology company focused on developing new therapies. The company is listed on the Nasdaq Stock Market. This legal action is proceeding as the firm investigates the company's public statements and disclosures.